Immune Checkpoint Inhibitors for Pediatric Cancers: Is It Still a Stalemate?

Area of Science:

• Pediatric Oncology
• Immunotherapy
• Cancer Research

Background:

• Immune checkpoint inhibitors (ICIs) are effective in adult cancers but show modest results in pediatric cancers.
• Pediatric cancers generally exhibit lower immunogenicity and fewer neoantigens compared to adult cancers.
• This disparity necessitates exploring specific pediatric cancer subsets for effective ICI application.

Purpose of the Study:

• To review the safety and efficacy of immune checkpoint inhibitors (ICIs) in pediatric patients with advanced malignancies.
• To analyze the current landscape of ICI treatment in pediatric oncology.
• To identify pediatric cancer types that may benefit from immunotherapy.

Main Methods:

• Systematic review of early-phase clinical trials (Phase I/II) involving ICIs in pediatric cancer patients.
• Analysis of response rates, safety profiles, and immunobiological factors influencing ICI efficacy.
• Focus on specific pediatric cancer subsets with potential for immunotherapy.

Main Results:

• Overall response rates for ICIs in pediatric cancers have been modest, with notable exceptions like pediatric classic Hodgkin lymphoma.
• Pediatric hypermutated and SMARCB1-deficient cancers have shown significant positive outcomes with ICI therapy.
• Underlying biological factors, including increased neoantigen expression and tumor inflammation, correlate with better ICI response.

Conclusions:

• While ICIs have limited efficacy in broad pediatric cancer populations, specific subsets demonstrate considerable promise.
• Further research and ongoing trials are crucial to optimize ICI therapy for identified pediatric cancer subgroups.
• Understanding tumor immunogenicity is key to advancing immunotherapy in pediatric oncology.